Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics Lays Off Approximately 100 Employees

NEW YORK – 10x Genomics has laid off approximately 8 percent of its full-time employees, or about 100 people, the firm disclosed in a regulatory filing with the US Securities and Exchange Commission on Wednesday.

"We took this action to make us more resilient in the current environment and put us on a path to become a sustainable business," Cofounder and CEO Serge Saxonov said in a statement on Thursday. "While all teams and locations were affected by yesterday’s actions, there was less impact in R&D and field-based customer-facing roles."

10x estimated it will incur costs in the range of $5 million to $6 million in conjunction with the staff reduction, primarily cash severance costs, which it plans to recognize in the third quarter.

The layoffs follow an announcement from 10x last month that its preliminary second quarter revenues were down 1 percent year over year.

10x's layoffs are the latest workforce cuts in the life sciences tools and diagnostics industry. Talis Biomedical cut its workforce by 35 percent this month; Invitae laid off more than 1,000 employees last month; and PerkinElmer, Siemens Healthineers, SummerBio, and Cue Health all laid off staff in June.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.